HIV Treatment Bulletin - Vol. 5, No. 9/10, October/November 2004
Graham McKerrow, HIV i-Base

A comparison between several generic antiretrovirals and the brand name formulations, carried out by researchers in Channai, India, and Boston, USA, shows that the drug content of the generics compared well. All the formulations were within the 5% range of the stated contents compared with the proprietary drugs, except for two.

Researchers at the Tuberculosis Research Centre in Chennai and Tufts University School of Medicine in Boston, analysed six widely used nucleoside and non-nucleoside reverse transcriptase inhibitors alone and in combination, from three Indian manufacturers: Aurobindo Pharma, Ranbaxy and Cipla.

They looked at efavirenz (600mg), nevirapine (200mg), AZT (300mg), ddI (250mg) d4T (30mg), 3TC (150mg), and a combination pill containing nevirapine, d4T and 3TC in those dosages and compared them to drugs manufactured in the USA. The samples analysed were physicians’ samples provided for patient use during July and August 2003.

Six tablets or capsules of each drug were crushed to a fine powder and analysed in duplicate by high performance liquid chromatography. In total, 12 chromatographic analyses were performed for each medication.

The researchers report that all the formulations were within the 5% range of the stated contents compared with the American products, except for stavudine and lamivudine “which were slightly higher but within the 10% range”. The authors add that their analyses “indicate that the amount of active drug is very similar to those medications manufactured in the USA”.

Ref: Ramachandran G, Perloff E, von Moltke L et al. Analysis of generic antiretroviral formulations manufactured in India. AIDS. 2004 Jul 2;18(10):1482-4.

041010
IB040510-06

©2004. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.